Skip to main content
Premium Trial:

Request an Annual Quote

LexaGene, Stanford Partner to Integrate Microfluidics, Targeted Sequencing for Cancer

NEW YORK (GenomeWeb) – LexaGene announced today that it will partner with the Stanford University School of Medicine to use cancer sequencing technology developed at the school in combination with the firm's microfluidic instrument.

LexaGene's technology involves single-use disposable microfluidic cartridges to concentrate and purify genetic samples, as well as an instrument to perform molecular analysis on the samples.

The platform is currently designed to be run with real-time PCR assays, and LexaGene has stated its intent to target the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.

The collaboration with Stanford will incorporate targeted sequencing technology developed by Stanford associate professor of genetics Hanlee Ji.

"LexaGene's technology was originally designed for pathogen detection across very large markets- I'm thrilled to report that we are working to expand our technology's capability to include cancer diagnostics and next generation sequencing," LexaGene CEO Jack Regan said in a statement.

In April, LexaGene announced its partnership with Ethos Veterinary Health to perform tests on canine urine samples using the firm's Lx6 prototype pathogen detection instrument.